Evidence map›Paper›PMID 41006713›Full record

ArticleScientific reports2025

Exploring PKMYT1 as a potential marker for colorectal cancer progression through bioinformatics analyses and experimental validation.

Yuqiang Zhang, Yingwei Chang, Yaorui Hu, Zhichao Ding, Zhihui Zhang, Yanbei Wei, Ben Liu, Minghao Yang, Wei Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuqiang ZhangDepartment of Laboratory Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710000, China.
Yingwei ChangDepartment of Geriatrics, Qingdao Huangdao District Central Hospital, Qingdao, 266000, China.
Yaorui HuInstitute of Neurobiology, Binzhou Medical University, Yantai, 264000, China.
Zhichao DingThe Second Medical College of Binzhou Medical University, Binzhou Medical University, Yantai, 264000, China.
Zhihui ZhangDepartment of Clinical Laboratory, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264100, China.
Yanbei WeiInstitute of Neurobiology, Binzhou Medical University, Yantai, 264000, China.
Ben LiuDepartment of Clinical Laboratory, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264100, China.
Minghao YangDepartment of Radiology, Yantai Affiliated Hospital of Binzhou Medical Universtiy, Yantai, 264100, China.
Wei ChenDepartment of Laboratory Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710000, China. chenweixjtu2014@126.com.

Funding

Medical and Health Science and Technology Development Project of Shandong Provincial 2019WS341Shandong Province Traditional Chinese Medicine Science and Technology Project M20244202
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a malignant tumor with high morbidity and mortality rates worldwide and only presents symptoms in later stage; no ideal biomarker is available for the early diagnosis of CRC. Therefore, it is important to explore novel molecules that significantly contribute to CRC progression. The cohort contains different stages of CRC were downloaded and comprehensive bioinformatics analyses were performed by Mfuzz, Protein-Protein Interaction (PPI), MCODE, ESTIMATE, and ssGSEA.The results revealed that Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) served as a functional hub gene and its high expression might be associated with an immunosuppressive microenvironment, therapeutic sensitivity and tumor progression. PKMYT1-related genes are linked to DNA replication, the cell cycle, and mismatch repair, indicating PKMYT1 functions as an oncogene and potential biomarker in CRC development. Moreover, in vitro experimental investigation was conducted and the data found that CRC tumor tissues and cells have elevated PKMYT1 expression. Knockdown of PKMYT1 by siRNAs significantly impaired the proliferation, cell cycling, migration, and invasion of CRC cells. In summary, this study demonstrated that PKMYT1 may be a promising target for therapeutic intervention and play a significant role in the development of CRC.

Indexed as

Biomarkers, TumorColorectal NeoplasmsComputational BiologyMembrane ProteinsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansProtein Interaction MapsBiomarkers, TumorMembrane ProteinsPKMYT1 protein, humanProtein Serine-Threonine KinasesProtein-Tyrosine KinasesBioinformatics analysisCRCPKMYT1Proliferation

Identifiers

PMID41006713
PMCPMC12475396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.